Skip to content
Learn8 min readStandard

Ketamine's Opioid Receptor Link to Antidepressant Effects

Does ketamine's antidepressant effect run through opioid receptors? Here's what the 2018 naltrexone trial found, and why later research disputes it.

Ketamine Resource Editorial Team··Reviewed by Ketamine Resource Editorial Review
Ketamine's Opioid Receptor Link to Antidepressant Effects article visual for Ketamine Resource

Editorial review

Educational content is reviewed for source quality, clinical boundaries, and readability. It is not medical advice; confirm care decisions with a licensed clinician.

Whether ketamine's antidepressant effect depends on opioid receptors is one of the more contested questions in ketamine research as of 2026. The leading explanation for ketamine's rapid mood effects centers on the NMDA receptor (N-methyl-D-aspartate receptor), a glutamate receptor that ketamine blocks, triggering a downstream signaling cascade. But a 2018 clinical trial raised a competing possibility: that ketamine's antidepressant action might also require activity at opioid receptors, the same receptor family that drugs like morphine and buprenorphine act on. That finding has not held up consistently in subsequent research, and researchers have not reached a consensus.

Quick Answer

The opioid-receptor hypothesis for ketamine's antidepressant effect is unconfirmed. A 2018 study in the American Journal of Psychiatry found that pretreating patients with the opioid blocker naltrexone reduced ketamine's antidepressant response in a small trial, suggesting opioid receptors might be involved. Later case reports, including a 2019 case series in JAMA Psychiatry, found ketamine still worked in patients already taking opioid-receptor blockers for other conditions, contradicting that result. The NMDA receptor antagonism and glutamate signaling model remains the most widely supported explanation for ketamine's antidepressant effect.

The 2018 Study That Started the Debate

The opioid-receptor question traces back to a small clinical trial led by Nolan Williams and colleagues at Stanford, published in the American Journal of Psychiatry in 2018. Researchers gave a group of adults with treatment-resistant depression either naltrexone, an opioid receptor antagonist (a drug that blocks opioid receptors) typically used to treat alcohol or opioid use disorder, or a placebo pill, about 45 minutes before a standard intravenous ketamine infusion (0.5 mg/kg).

Patients who received naltrexone before ketamine showed a smaller improvement in depression scores than those who received a placebo before ketamine, measured on the Montgomery-Åsberg Depression Rating Scale (MADRS). The researchers reported this as evidence that opioid receptor activity might be necessary for ketamine's antidepressant effect, since blocking those receptors seemed to blunt the response. You can review the original Williams et al. study on PubMed.

This was a notable finding because ketamine is already known to bind weakly to mu-opioid receptors at clinical doses, alongside its primary action on NMDA receptors. The study suggested that overlap might not be incidental to how ketamine lifts mood.

Why Later Research Pushed Back

The naltrexone finding drew scrutiny almost immediately, in part because the sample size was small (about 12 to 14 patients per group) and because it ran against decades of NMDA-focused mechanism research. Subsequent case reports complicated the picture further.

A 2019 case series by Guy Yoon, Ismene Petrakis, and John Krystal, published in JAMA Psychiatry, described patients with co-occurring depression and alcohol use disorder who were already taking naltrexone as part of their addiction treatment. When those patients received ketamine infusions for depression, several still showed meaningful improvement in depressive symptoms, despite having opioid receptors pharmacologically blocked at the time. You can review that case series on PubMed. Other research groups attempting to replicate the original naltrexone-blockade effect have reported mixed or null results.

The disagreement between these studies illustrates a broader pattern in ketamine research: small trials with promising or provocative results do not always hold up when other labs test the same question with different patient populations. For a closer look at why that happens, see how to read ketamine depression research studies.

Compare evidence and options

Compare ketamine with other treatment paths using neutral explainers.

Compare options

Ketamine is basically an opioid.

Ketamine's primary pharmacological action is blocking NMDA receptors, a glutamate receptor system unrelated to how opioids work. Any interaction with opioid receptors appears to be a secondary, weaker effect, and researchers disagree about how much it contributes to ketamine's antidepressant action.

The 2018 naltrexone finding proved ketamine's antidepressant effect works through opioid receptors.

One small trial reported this result, but later case reports found ketamine still worked in some patients on opioid-receptor blockers. The hypothesis remains unconfirmed, not established.

Why This Matters If You Take an Opioid-Blocking Medication

If you take naltrexone (including the extended-release injection Vivitrol), buprenorphine, or another medication that affects opioid receptors, this research is relevant to a conversation with your prescriber, not a reason to stop or start any medication on your own. The 2018 trial suggests these drugs might reduce ketamine's antidepressant effect for some people, even though later evidence is mixed. A prescriber weighing ketamine or esketamine (Spravato) treatment should know about any opioid-receptor medication you take, since it could factor into how they set expectations for your response. For related mechanism context, see ketamine HCN1 receptor antidepressant mechanism, and for patient-specific factors clinicians weigh before treatment, see a psychiatrist's outline of ketamine patient considerations.

Tell Your Prescriber About Opioid-Receptor Medications

If you currently take naltrexone, buprenorphine, methadone, or any other medication affecting opioid receptors, tell your prescriber before starting ketamine or esketamine treatment. This is educational information, not medical advice. Only a licensed clinician familiar with your full medication history and health history can assess how this might apply to you.

The Bigger Picture: More Than One Mechanism in Play

The opioid-receptor question is one strand in a larger research effort to explain how ketamine produces antidepressant effects within hours, far faster than traditional antidepressants, which typically take weeks. The dominant model involves NMDA receptor blockade leading to a glutamate surge, which activates AMPA receptors and downstream signaling pathways (including BDNF and mTOR) tied to synapse formation. Researchers are also studying ketamine's active metabolites, including norketamine and hydroxynorketamine, covered in this breakdown of ketamine metabolites, since these may contribute independently to mood effects. No single receptor or pathway fully explains the antidepressant response, and the opioid-receptor hypothesis is one open thread among several, not a settled alternative to the NMDA model.

Compare Ketamine Treatment Methods

Mechanism research helps explain how ketamine works, but choosing between IV, intranasal, oral, and esketamine routes depends on other factors too. See how the options compare.

Frequently Asked Questions

Not directly. Ketamine carries its own misuse and dependence risks, documented separately from opioid pharmacology, but the 2018 naltrexone finding was about antidepressant mechanism, not about abuse potential. Ketamine's primary receptor action (NMDA blockade) is distinct from the opioid receptor system that drives opioid dependence.

Do not change or stop any prescribed medication without talking to the prescriber who manages it. If you are considering ketamine or esketamine treatment, tell both prescribers about all medications you take so they can coordinate on your specific situation.

Yes. As of 2026, researchers continue to investigate how much, if any, of ketamine's antidepressant effect involves opioid receptors, alongside the better-supported NMDA receptor and glutamate signaling model. No large, consistently replicated trial has confirmed or ruled out a meaningful opioid-receptor role.

The 2018 trial and its follow-up studies used intravenous racemic ketamine, not esketamine. Esketamine (Spravato) is the only ketamine-related treatment with FDA approval, specifically for treatment-resistant depression, and it has not been studied in the same naltrexone-blockade trials, so it is unclear whether the same findings would apply.

Share

Contact Ketamine Resource

Send corrections, partnership questions, or advertising inquiries.

Contact the site